delta-9-THC - General Information
A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound. Dronabinol is a synthetic form of delta-9-THC. [PubChem]
Pharmacology of delta-9-THC
Dronabinol may has complex effects on the central nervous system (CNS), including cannabinoid receptors. Dronabinol may inhibit endorphins in the emetic center, suppress prostaglandin synthesis, and/or inhibit medullary activity through an unspecified cortical action.
delta-9-THC for patients
Patients receiving treatment with MARINOL (Dronabinol) Capsules should be alerted to the potential
for additive central nervous system depression if MARINOL Capsules is used concomitantly with alcohol
or other CNS depressants such as benzodiazepines and barbiturates.
Patients receiving treatment with MARINOL Capsules should be specifically warned not to drive, operate
machinery, or engage in any hazardous activity until it is established that they are able to tolerate
the drug and to perform such tasks safely.
Patients using MARINOL Capsules should be advised of possible changes in mood and other adverse behavioral
effects of the drug so as to avoid panic in the event of such manifestations. Patients should remain under
the supervision of a responsible adult during initial use of MARINOL Capsules and following dosage
Interactions for Dronabinol:
In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions. Although no drug/drug interactions were discovered during the clinical trials of MARINOL Capsules, cannabinoids may interact with other medications through both metabolic and pharmacodynamic mechanisms. Dronabinol is highly protein bound to plasma proteins, and therefore, might displace other protein-bound drugs. Although this displacement has not been confirmed in vivo, practitioners should monitor patients for a change in dosage requirements when administering dronabinol to patients receiving other highly protein-bound drugs.
Contraindications for Dronabinol:
Dronabinol capsules is contraindicated in any patient who has a history of hypersensitivity to any cannabinoid or sesame oil.
Additional information about delta-9-THC
delta-9-THC Indication: For the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
Mechanism Of Action: The mechanism of action of dronabinol is not completely understood. It is thought that cannabinoid receptors in neural tissues may mediate the effects of dronabinol and other cannabinoids. Animal studies with other cannabinoids suggest that dronabinol's antiemetic effects may be due to inhibition of the vomiting control mechanism in the medulla oblongata.
Drug Interactions: Not Available
Food Interactions: Take without regard to meals.
Generic Name: Marinol
Synonyms: Not Available
Drug Category: Analgesics; Psychotropic Drugs; Hallucinogens; Antiemetics
Drug Type: Small Molecule; Illicit; Approved
Absorption: 90 - 95%
Toxicity (Overdose): Not Available
Protein Binding: 97%
Half Life: Alpha phase: approximately 4 hours; Beta phase: 25-36 hours
Dosage Forms of delta-9-THC: Capsule Oral
Chemical IUPAC Name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Chemical Formula: C21H30O2
Marinol on Wikipedia: https://en.wikipedia.org/wiki/Marinol
Organisms Affected: Humans and other mammals